Still, the FDA said that, Many of the adverse events reported for compounded products appear to be consistent with adverse events related to the FDA-approved versions of these products
The trial reported a 26% reduction in the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
Hartikainen et al., 1992), although there are studies which have described increased (Ruberg et al., 1986), decreased (Konings et al., 1995), or normal activity (Zubenko et al., 1986
It is recommended to start a course of weekly treatments for ideal results
Also, all the supra-therapeutic doses of CGV used in this study did not significantly alter testosterone levels in rats